Patents by Inventor Robert F. Dunn

Robert F. Dunn has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • PROCESS FOR MAKING BETA 3 AGONISTS AND INTERMEDIATES
    Publication number: 20150087832
    Abstract: The present invention is directed to processes for preparing beta 3 agonists of Formula (I) and Formula (II) and their intermediates. The beta 3 agonists are useful in the treatment of certain disorders, including overactive bladder, urinary incontinence, and urinary urgency.
    Type: Application
    Filed: October 22, 2012
    Publication date: March 26, 2015
    Applicant: MERCK SHARP & DOHME, CORP.
    Inventors: John Y.L. Chung, Kevin Campos, Edward Cleator, Robert F. Dunn, Andrew Gibson, R. Scott Hoerrner, Stephen Keen, Dave Liebermann, Zhuqing Liu, Joseph Lynch, Kevine M. Maloney, Feng Xu, Nobuyoshi Yasuda, Naoki Yoshikawa, Yong-Li Zhong
  • PROCESS FOR MAKING BETA 3 AGONISTS AND INTERMEDIATES
    Publication number: 20140242645
    Abstract: The present invention is directed to a process for preparing a compound of formula I-11 through multiple-step reactions.
    Type: Application
    Filed: October 22, 2012
    Publication date: August 28, 2014
    Inventors: John Y.L. Chung, Kevin Campos, Edward Cleator, Robert F. Dunn, Andrew Gibson, R Scott Hoerrner, Stephen Keen, Dave Lieberman, Zhuqing Liu, Joseph Lynch, Kevin M. Maloney, Feng Xu, Nobuyoshi Yasuda, Naoki Yoshikawa, Yong-Li Zhong
  • PROCESS FOR PREPARING CHIRAL DIPEPTIDYL PEPTIDASE-IV INHIBITORS
    Publication number: 20140107346
    Abstract: A process for the preparation of pyrazolopyrolidines of structural formula I: and W is or P, wherein in P is an amine protecting group. These compounds are useful in the synthesis of dipeptidyl peptidase-IV inhibitors for the treatment of Type 2 diabetes. Also provided are useful intermediates obtained from the process.
    Type: Application
    Filed: June 25, 2012
    Publication date: April 17, 2014
    Applicants: Merck Sharp & Dohme Ltd., Merck Sharp & Dohme Corp.
    Inventors: Michael J. Zacuto, Robert F. Dunn, Aaron J. Moment, Jacob M. Janey, David Lieberman, Faye Sheen, Nadine Bremeyer, Jeremy Scott, Jeffrey T. Kuethe
  • Phosphodiesterase 4 inhibitors
    Patent number: 7723348
    Abstract: Selective PDE4 inhibition is achieved by aryl and heteroaryl pyrazole compounds. The compounds exhibit improved PDE4 inhibition as compared to compounds such as rolipram and show selectivity with regard to inhibition of other classes of PDEs.
    Type: Grant
    Filed: April 24, 2008
    Date of Patent: May 25, 2010
    Assignee: Memory Pharmaceuticals Corporation
    Inventors: Allen Hopper, Robert F. Dunn, Erik Mikal Kuester, Richard D. Conticello
  • Phosphodiesterase 4 inhibitors
    Patent number: 7696198
    Abstract: Selective PDE4 inhibition is achieved by 4-(substituted-phenyl)-2-pyrrolidinone compounds. The compounds exhibit improved PDE4 inhibition as compared to compounds like rolipram and show selectivity with regard to inhibition of other classes of PDEs. The compounds of the present invention are of formula I: wherein R1, R2, and R3 are as defined herein.
    Type: Grant
    Filed: April 16, 2004
    Date of Patent: April 13, 2010
    Assignee: Memory Pharmaceuticals Corporation
    Inventors: Ashok Tehim, Allen Hopper, Ruiping Liu, Erik Kuester, Robert F. Dunn, Thomas E. Renau
  • PHOSPHODIESTERASE 4 INHIBITORS
    Publication number: 20100029689
    Abstract: PDE4 inhibition is achieved by novel compounds, e.g., N-substituted aniline and diphenylamine analogs. The compounds of the present invention are of Formula I: wherein R1, R2, R3, and R4 are as defined herein.
    Type: Application
    Filed: July 2, 2009
    Publication date: February 4, 2010
    Applicants: MEMORY PHARMACEUTICALS CORPORATION, ROCHE PALO ALTO LLC
    Inventors: Allen T. HOPPER, Joan Marie CAROON, Elbert CHIN, Robert F. DUNN, Sharada Shenvi LABADIE, Jim LI, Richard Allen SCHUMACHER, Francisco Xavier TALAMAS
  • PHOSPHODIESTERASE 4 INHIBITORS, INCLUDING N-SUBSTITUTED ANILINE AND DIPHENYLAMINE ANALOGS
    Publication number: 20090048255
    Abstract: PDE4 inhibition is achieved by novel compounds, e.g., N-substituted aniline and diphenylamine analogs. The compounds of the present invention are of Formula I: wherein R1, R2, R3 and R4 are as defined herein.
    Type: Application
    Filed: July 17, 2008
    Publication date: February 19, 2009
    Inventors: Richard A. SCHUMACHER, Allen T. HOPPER, Ashok TEHIM, Hans-Jurgen Ernst HESS, Axel UNTERBECK, Erik KUESTER, William Frederick BRUBAKER, JR., Robert F. DUNN
  • Phosphodiesterase 4 inhibitors
    Patent number: 7432266
    Abstract: Selective PDE4 inhibition is achieved by aryl and heteroaryl pyrazole compounds. The compounds exhibit improved PDE4 inhibition as compared to compounds such as rolipram and show selectivity with regard to inhibition of other classes of PDEs.
    Type: Grant
    Filed: October 14, 2005
    Date of Patent: October 7, 2008
    Assignee: Memory Pharmaceuticals Corporation
    Inventors: Allen Hopper, Robert F. Dunn, Erik Mikal Kuester, Richard D. Conticello
  • PHOSPHODIESTERASE 4 INHIBITORS
    Publication number: 20080207660
    Abstract: Selective PDE4 inhibition is achieved by aryl and heteroaryl pyrazole compounds. The compounds exhibit improved PDE4 inhibition as compared to compounds such as rolipram and show selectivity with regard to inhibition of other classes of PDEs.
    Type: Application
    Filed: April 24, 2008
    Publication date: August 28, 2008
    Inventors: Allen HOPPER, Robert F. Dunn, Erik Mikal Kuester, Richard D. Conticello
  • Phosphodiesterase 4 inhibitors, including N-substituted aniline and diphenylamine analogs
    Patent number: 7405230
    Abstract: PDE4 inhibition is achieved by novel compounds, e.g., N-substituted aniline and diphenylamine analogs. The compounds of the present invention are of Formula I: wherein R1, R2, R3 and R4 are as defined herein.
    Type: Grant
    Filed: July 21, 2003
    Date of Patent: July 29, 2008
    Assignee: Memory Pharmaceuticals Corporation
    Inventors: Richard A. Schumacher, Allen T. Hopper, Ashok Tehim, Hans-Jurgen Ernst Hess, Axel Unterbeck, Erik Kuester, William Frederick Brubaker, Jr., Robert F. Dunn